Allopregnanolone Chemiluminescent Immunoassay Kit

Features

  • Multi Species
  • SENSITIVE - Measure from 5,000 to 78.125 pg/mL
  • SAMPLE - Extracted Serum, Plasma, Fecal, and Urine or TCM
  • SAMPLES/KIT - 39 or 231 in Duplicate
  • SELECTIVE - Low Cross Reactivity to Progesterone and Metabolites

Our Allopregnanolone Chemiluminescent Immunoassay Kit (K044-C) will be discontinued on October 1, 2019. This kit is being replaced with our Allopregnanolone EIA Kit, Monoclonal Antibody Based (K061-H) which is now available.

The DetectX® Allopregnanolone Chemiluminescent Immunoassay (CLIA) kit is designed to quantitatively measure Allopregnanolone present in extracted serum, plasma, or dried fecal samples, or in diluted urine and tissue culture media samples.  An allopregnanolone standard is provided to generate a standard curve for the assay and all samples should be read off the standard curve.  Standards or samples are pipetted into a white microtiter plate coated with antibody to capture rabbit antibodies.  An allopregnanolone-peroxidase conjugate is added to the wells and the binding reaction is initiated by addition of a polyclonal antibody to allopregnanolone to each well.  The assay is incubated overnight at 4˚C.  At the end of the incubations period the plate is washed and chemiluminescent substrate is added.  The chemiluminescent substrate reacts with the bound allopregnanolone-peroxidase conjugate to generate light.

Allopregnanolone aids neurogenesis and has been found to reverse neuron proliferative deficit and cognitive deficits in a mouse model of Alzheimer’s disease. Allopregnanolone has also been shown to restore functionality in a mouse model of Parkinson’s Disease. It has also been shown to improve behavioral problems in post-traumatic stress disorder.

K044-C

Data Reduction Template by MyAssays

Subscribe to our mailing list

Sign up to our e-mail newsletter and receive updates and special offers.

X

Come visit us at the Pan American Neuroendocrine Society and Endocrinology Society Meeting in New Orleans, LA, March 21-26, 2019